Drivers and barriers to patient participation in RCTs

V Jenkins, V Farewell, D Farewell, J Darmanin, J Wagstaff, C Langridge, L Fallowfield, TTT Steering committee, Libby Batt, Jayne Caparros, Ty Francis, Jane James, Jayne Jones, Kathy Malinovsky, Tim Maughan, Fergus Macbeth, Margaret Moore, Jackie Morris, Sara Shankland, Lucy Seago, John Wagstaff, Richard Adams, Peter Barrett-Lee, Michael Chare, Derek Crawford, David Edwards, Alan Evans, Mererid Evans, Eve Gallop- Evans, Simon Gollins, Neil Fenn, Simon Holt, Saad Al Ismael, Mike Jamieson, Richard Johnson, Tibor Kovacs, Howard Kynaston, Simon Leeson, Seamus Linnane, Bill Maxwell, Andrew Maw, Diane Parry, Clare Rowntree, V Jenkins, V Farewell, D Farewell, J Darmanin, J Wagstaff, C Langridge, L Fallowfield, TTT Steering committee, Libby Batt, Jayne Caparros, Ty Francis, Jane James, Jayne Jones, Kathy Malinovsky, Tim Maughan, Fergus Macbeth, Margaret Moore, Jackie Morris, Sara Shankland, Lucy Seago, John Wagstaff, Richard Adams, Peter Barrett-Lee, Michael Chare, Derek Crawford, David Edwards, Alan Evans, Mererid Evans, Eve Gallop- Evans, Simon Gollins, Neil Fenn, Simon Holt, Saad Al Ismael, Mike Jamieson, Richard Johnson, Tibor Kovacs, Howard Kynaston, Simon Leeson, Seamus Linnane, Bill Maxwell, Andrew Maw, Diane Parry, Clare Rowntree

Abstract

Background: Recruitment of patients into randomised clinical trials (RCTs) is essential for treatment evaluation. Appreciation of the barriers and drivers towards participation is important for trial design, communication and information provision.

Method: As part of an intervention to facilitate effective multidisciplinary team communication about RCTs, cancer patients completed two study-specific questionnaires following trial discussions. One questionnaire examined reasons why patients accepted or declined trial entry, the other perceptions about their health-care professionals' (HCPs) information giving.

Results: Questionnaires were completed by 74% (358/486) of patients approached; of these 81% (291/358) had joined an RCT, 16% (56/358) had declined and 3% (11/358) were undecided. Trial participation status of the 128 patients not returning questionnaires is unknown. Trial acceptance was not dependent on disease stage, tumour type, sex or age. Satisfaction with trial information and HCPs' communication was generally very good, irrespective of participation decisions. The primary reason given for trial acceptance was altruism (40%; 110/275), and for declining, trust in the doctor (28%; 12/43). Decliners preferred doctors to choose their treatment rather than be randomised (54% vs 39%; P<0.027). Acceptors were more likely to perceive doctors as wanting them to join trials (54% vs 30%; P<0.001). Trial type, that is, standard treatment vs novel or different durations of treatment, also influenced acceptance rates.

Conclusion: The drivers and barriers to trial participation are partly related to trial design. Unease about randomisation and impact of duration on treatment efficacy are barriers for some. Altruism and HCPs' perceived attitudes are powerful influencing factors.

References

    1. Buss MK, DuBenske LL, Dinauer S, Gustafson DH, McTavish F, Cleary JF. Patient/caregiver influences for declining participation in supportive oncology trials. J Suppor Oncol. 2008;6 (4:168–174.
    1. Catt S, Langridge C, Fallowfield L, Talbot DC, Jenkins V. Reasons given by patients for participating, or not, in Phase 1 cancer trials. EJC. 2011;47 (10:1490–1497.
    1. Daugherty C, Ratain MJ, Grochowski E, Stocking C, Kodish E, Mick R, Siegler M. Perceptions of cancer patients and their physicians involved in phase I trials. JCO. 1995;13 (5:1062–1072.
    1. Fallowfield LJ, Jenkins VA, Brennan C, Sawtell M, Moynihan C, Souhami RL. Patients' attitudes to randomised clinical trials of cancer therapy. EJC. 1998;34 (10:1554–1559.
    1. Fallowfield LJ, Solis-Trapala I, Jenkins VA. Evaluation of an educational program to improve communication with patients about early phase trial participation. Oncologist. 2012;17 (7:377–383.
    1. Ford E, Jenkins V, Fallowfield L, Stuart N, Farewell D, Farewell V. Clinicians' attitudes towards clinical trials of cancer therapy. BJC. 2011;104 (10:1535–1543.
    1. Garcea G, Lloyd T, Steward WP, Dennison AR, Berry DP. Differences in attitudes between patients with primary colorectal cancer and patients with secondary colorectal cancer: is it reflected in their willingness to participate in drug trials. EJCC. 2005;14 (2:166–170.
    1. Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomised clinical trials for cancer therapy. BJC. 2001;82 (11:1783–1788.
    1. Jenkins V, Farewell D, Batt L, Maughan T, Branston L, Langridge C, Parlour L, Farewell V, Fallowfield LJ. The attitudes of 1066 patients with cancer towards participation in randomised clinical trials. BJC. 2010;103:1801–1807.
    1. Locock L, Smith L. Personal benefit, or benefiting others? Deciding whether to take part in clinical trials. Clin Trials. 2011;8 (1:85–93.
    1. McCann SK, Campbell MK, Entwistle VA, Smith D.2010Reasons for participating in randomised controlled trials: conditional altruism and considerations for self Trials 11art. no31.
    1. Penman DT, Holland JC, Bahna GF, Morrow G. Informed consent for investigational chemotherapy: patients' and physicians' perceptions. JCO. 1984;2:849–855.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever